Related Experiment Videos
Targeting IL-23 in Crohn's disease
Silvia Sedda1, Gerolamo Bevivino1, Giovanni Monteleone1
1a Department of Systems Medicine , University of Rome "Tor Vergata" , Rome , Italy.
Expert Review of Clinical Immunology
|September 19, 2018
Summary
Interleukin-23 (IL-23) plays a key role in Crohn's disease (CD) pathogenesis. Blocking IL-23 shows promise as a new therapy for patients with inflammatory bowel disease who do not respond to existing treatments.
Area of Science:
- Immunology
- Gastroenterology
- Inflammatory Bowel Disease
Background:
- Interleukin-23 (IL-23) is a cytokine implicated in inflammatory pathways.
- Genome-wide association studies and animal models link IL-23 to Crohn's disease (CD) pathogenesis.
- Existing CD treatments like anti-TNF and anti-integrins are insufficient for a significant patient proportion.
Purpose of the Study:
- To review the role of IL-23 in Crohn's disease.
- To discuss the therapeutic potential of targeting IL-23 in CD management.
Main Methods:
- Literature review of studies on IL-23 in CD.
- Analysis of clinical trial data for IL-23 inhibitors.
Main Results:
- IL-23 is a validated therapeutic target for CD.
- IL-23 inhibitors are emerging as a promising treatment option.
Conclusions:
- Targeting IL-23 offers a new therapeutic avenue for CD patients.
- Further research is needed to optimize IL-23 blockade strategies and assess long-term safety.